Blue Cross and Blue Shield of Illinois policy
Management of Hereditary Angioedema (HAE) with C1 Esterase Inhibitor, Human and Ecallantide
Management of Hereditary Angioedema (HAE) with C1 Esterase Inhibitor, Human and Ecallantide is a public Blue Cross and Blue Shield of Illinois policy (policy RX504.013, effective Jan 1, 2026). It lists 2 CPT or HCPCS codes. Not a coverage decision; the payer's own document governs.
View the original policy (PDF) ↗
- Policy number
- RX504.013
- Effective
- Jan 1, 2026
- Line of business
- Commercial, Medicaid
- Source
- medicalpolicy.hcsc.com
Codes in this policy
The CPT and HCPCS codes the policy names. A policy can name a code it excludes.
| Code | Other Blue Cross and Blue Shield of Illinois policies |
|---|---|
| J0598 | Policies naming J0598 |
| J1290 | Policies naming J1290 |